[go: up one dir, main page]

AR132703A1 - Compuestos tricíclicos y usos de los mismos - Google Patents

Compuestos tricíclicos y usos de los mismos

Info

Publication number
AR132703A1
AR132703A1 ARP240101243A ARP240101243A AR132703A1 AR 132703 A1 AR132703 A1 AR 132703A1 AR P240101243 A ARP240101243 A AR P240101243A AR P240101243 A ARP240101243 A AR P240101243A AR 132703 A1 AR132703 A1 AR 132703A1
Authority
AR
Argentina
Prior art keywords
tricyclic compounds
tricyclic
compounds
preparing
variable
Prior art date
Application number
ARP240101243A
Other languages
English (en)
Inventor
Weihan Zhang
Kun Xiao
Zheng Zhang
Yao Wu
Wei-Guo Su
Original Assignee
Hutchmed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchmed Ltd filed Critical Hutchmed Ltd
Publication of AR132703A1 publication Critical patent/AR132703A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con compuestos tricíclicos de la fórmula (1), composiciones farmacéuticas que los comprenden, métodos de preparación de los mismos y sus usos, en donde cada variable es como se define en la descripción.
ARP240101243A 2023-05-16 2024-05-16 Compuestos tricíclicos y usos de los mismos AR132703A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202310552365 2023-05-16
CN202311459371 2023-11-03
CN202410149082 2024-02-01
CN202410567016 2024-05-09

Publications (1)

Publication Number Publication Date
AR132703A1 true AR132703A1 (es) 2025-07-23

Family

ID=93518720

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101243A AR132703A1 (es) 2023-05-16 2024-05-16 Compuestos tricíclicos y usos de los mismos

Country Status (4)

Country Link
CN (1) CN121194980A (es)
AR (1) AR132703A1 (es)
TW (1) TW202509040A (es)
WO (1) WO2024235286A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025096738A1 (en) * 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
TW202539672A (zh) * 2024-02-06 2025-10-16 大陸商上海齊魯製藥研究中心有限公司 嘧啶并大環類kras抑制劑
WO2025168072A1 (en) * 2024-02-08 2025-08-14 Beigene (Suzhou) Co., Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216762A1 (en) * 2021-04-08 2022-10-13 Genentech, Inc. Oxazepine compounds and uses thereof in the treatment of cancer
WO2023046135A1 (en) * 2021-09-27 2023-03-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
CN116332948A (zh) * 2021-12-22 2023-06-27 翰森生物有限责任公司 一种含氮四环化合物及其制备方法和药用用途
KR20240163107A (ko) * 2022-03-11 2024-11-18 컴쿼트 바이오사이언시즈 인크. 헤테로환 화합물 및 이의 용도
CR20240556A (es) * 2022-07-05 2025-01-29 Pfizer Compuestos de pirido[4,3-d]pirimidina
CA3261298A1 (en) * 2022-07-09 2024-01-18 Blossomhill Therapeutics, Inc. Fused-cycle Kras inhibitors for the treatment of a disease
CN119677754A (zh) * 2022-08-11 2025-03-21 百济神州(苏州)生物科技有限公司 杂环化合物、其组合物及用其进行治疗的方法
TW202408512A (zh) * 2022-08-12 2024-03-01 大陸商正大天晴藥業集團股份有限公司 三環類化合物及其醫藥用途
WO2024041621A1 (en) * 2022-08-25 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
CN120077050A (zh) * 2022-10-18 2025-05-30 伊迪恩斯股份有限公司 新颖三杂环化合物
WO2024083168A1 (en) * 2022-10-19 2024-04-25 Genentech, Inc. Oxazepine compounds comprising a 6-aza moiety and uses thereof
CN120282969A (zh) * 2022-11-17 2025-07-08 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
WO2024120419A1 (en) * 2022-12-06 2024-06-13 Zai Lab (Shanghai) Co., Ltd. Fused tetracyclic compounds as kras g12d modulators and uses thereof

Also Published As

Publication number Publication date
TW202509040A (zh) 2025-03-01
CN121194980A (zh) 2025-12-23
WO2024235286A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
AR132703A1 (es) Compuestos tricíclicos y usos de los mismos
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
CL2022002574A1 (es) Compuestos de amida y usos de los mismos
CR20220200A (es) Compuestos de heteroarilo bicíclicos y usos de estos
DOP2011000361A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cancer y otras enfermedades
CL2023002274A1 (es) Compuestos tricíclicos y usos de los mismos
CL2025002304A1 (es) Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos
CO2022016899A2 (es) Moduladores de il-17a
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
CL2022002255A1 (es) Compuestos heterocíclicos de heteroarilo y usos de los mismos
CO2023000056A2 (es) Derivados de amidopirimidona
CO2022018636A2 (es) Moduladores de il-17a
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
CL2022002661A1 (es) Derivados de benzodiazepinas como pam de gaba a gamma1
CL2024001635A1 (es) Compuestos de diazaspiro sustituidos con carbonilo y su uso
CL2023000772A1 (es) Compuestos heterocíclicos de heteroarilo y usos de los mismos
CL2021000381A1 (es) Fosforamiditas de nucleósido modificado. (divisional de solicitud 202000657)
CL2024000313A1 (es) (3-quinolil)-quinazolina
CL2024000316A1 (es) (3-piridil)-quinazolina
ECSP099679A (es) Nuevos compuestos y sus usos 707
CL2021000973A1 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CO2023000858A2 (es) Inhibidores de atr y usos de estos
CL2024002273A1 (es) Pirazolopirimidinas, composiciones que las comprenden y usos de las mismas.
CL2020002058A1 (es) Piridincarboxamidas novedosas.
CL2025000551A1 (es) Compuestos de triazina y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure